The use of immunological markers in IDDM after more than 20 years from ICA description.
Dotta
F
F
Clinica Medica 2-Endocrinologia, University of Rome La Sapienza, Italy.
Dionisi
S
S
Farilla
L
L
Di Mario
U
U
D000818:Animals; D001323:Autoantibodies / Q000276:immunology*; D015415:Biomarkers; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology*; D005732:Gangliosides / Q000276:immunology; D005968:Glutamate Decarboxylase / Q000276:immunology; D006801:Humans; D007330:Insulin Antibodies / Q000276:immunology; D007515:Islets of Langerhans / Q000276:immunology; D051379:Mice; D054562:Protein Tyrosine Phosphatase, Non-Receptor Type 1; D017027:Protein Tyrosine Phosphatases / Q000276:immunology
D001323:Autoantibodies; D015415:Biomarkers; C098337:GM2-1 ganglioside; D005732:Gangliosides; D007330:Insulin Antibodies; C024211:islet cell antibody; D054562:Protein Tyrosine Phosphatase, Non-Receptor Type 1; D017027:Protein Tyrosine Phosphatases; D005968:Glutamate Decarboxylase